The Medicines Company is a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of medicines to the worldwide hospital marketplace. The Company has two marketed products, Angiomax (bivalirudin) and Cleviprex (clevidipine butyrate) injectable emulsion, two products in late-stage development, cangrelor and oritavancin, which the Company acquired in February 2009, and one compound, CU-2010, scheduled to enter clinical development during 2009.